Ivan Macharashvili
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ivan Macharashvili has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Marchioni
Hospital Alemán, CABA, Buenos Aires, Argentina
2 shared publications - Augusto Ferreyra Camacho
CABA, Hospital Universitario Austral, Buenos Aires, Argentina
2 shared publications - Gonzalo Taetti
Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC), CABA, Buenos Aires, Argentina
2 shared publications Hernan Cutuli
Entre Ríos, Hospital Sirio Libanes, Buenos Aires, Argentina
2 shared publications- Aldo Perfetti
Centro CEMIC, Buenos Aires, Argentina
1 shared publication Carlos Brocca
Hospital Privado de Córdoba, Córdoba, Argentina
1 shared publication
Latest Publications
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (8)
Genomic Landscape of Metastatic Urothelial Cancer in a Multicenter Cohort From Argentina
PURPOSE: The genomic landscape of advanced urothelial carcinoma (aUC) has enabled the development of targeted therapies; however, real-world data from Latin America remain limited. MATERIALS AND METHODS: We conducted a multicenter retrospective study including patients with aUC who underwent next-generation sequencing on tumor tissue. Molecular alterations were classified according to the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT). RESULTS: A total of 107 patients were included. Overall, 68 patients (63.6%) harbored at least one potentially actionable molecular alteration. Among these, 34 patients (31.8%) exhibited ESCAT level I alterations, most commonly involving FGFR3 mutations/fusions and ERBB2 amplification. CONCLUSION: A clinically meaningful proportion of Argentine patients with aUC harbor ESCAT level I actionable alterations, supporting the incorporation of routine genomic profiling into clinical practice.
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (8)
Genomic Landscape of Metastatic Urothelial Cancer in a Multicenter Cohort From Argentina
PURPOSE: The genomic landscape of advanced urothelial carcinoma (aUC) has enabled the development of targeted therapies; however, real-world data from Latin America remain limited. MATERIALS AND METHODS: We conducted a multicenter retrospective study including patients with aUC who underwent next-generation sequencing on tumor tissue. Molecular alterations were classified according to the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT). RESULTS: A total of 107 patients were included. Overall, 68 patients (63.6%) harbored at least one potentially actionable molecular alteration. Among these, 34 patients (31.8%) exhibited ESCAT level I alterations, most commonly involving FGFR3 mutations/fusions and ERBB2 amplification. CONCLUSION: A clinically meaningful proportion of Argentine patients with aUC harbor ESCAT level I actionable alterations, supporting the incorporation of routine genomic profiling into clinical practice.
- 13 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2600677
From Guidelines to Practice: Mainstreaming Germline Testing in Prostate Cancer
- 13 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2600677
From Guidelines to Practice: Mainstreaming Germline Testing in Prostate Cancer
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500014
Real-World Outcomes in Anaplastic Lymphoma Kinase–Positive Advanced Non–Small Cell Lung Cancer in Argentina: A Multicenter Retrospective Study (GAOT-ALK001)
PURPOSE: In Argentina, anaplastic lymphoma kinase (ALK) gene rearrangements occur in approximately 6.1% of non–small cell lung cancer (NSCLC) cases. Given the availability of second- and third-generation ALK inhibitors, real-world data are needed to inform optimal treatment strategies. However, access to these therapies remains limited for many patients. METHODS: We conducted a multicenter retrospective study of patients with metastatic ALK-positive NSCLC (ALKp) treated with first-line tyrosine kinase inhibitors (TKIs) from January 2014 to February 2024. Demographics, treatment patterns, clinical outcomes, and factors affecting treatment accessibility were analyzed. RESULTS: We identified 104 patients with ALKp. The median age was 55 years (IQR, 45-67); 86% had Eastern Cooperative Oncology Group ≤1, 58% were women, and 57% were nonsmokers. Brain metastases were present at diagnosis in 29%, with 50% receiving local treatment. First-line TKIs included alectinib (42%), crizotinib (30%), lorlatinib (16%), and brigatinib (12%). Crizotinib use was frequently due to limited access to new-generation TKIs. Adverse events occurred in 54%, with 21% grade 3 to 4. The objective response rate was 73%. At a median follow-up of 42 months, 48% experienced progression. Crizotinib was associated with higher risk of progression or death compared with newer TKIs (hazard ratio, 3.09 [95% CI, 1.75 to 5.5]; P = .01). CNS progression occurred in 18%, more often with crizotinib (42% v 8%, P = .04). Among those progressing, 82% received second-line therapy, most commonly lorlatinib or alectinib. The overall survival at 24 months was 81%, with 27% of patients deceased at data cutoff. CONCLUSION: This real-world study describes outcomes and treatment patterns among patients with ALKp in Argentina. It highlights disparities in access to optimal therapies and reinforces the need for equitable access to new-generation ALK inhibitors to improve clinical outcomes.
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500014
Real-World Outcomes in Anaplastic Lymphoma Kinase–Positive Advanced Non–Small Cell Lung Cancer in Argentina: A Multicenter Retrospective Study (GAOT-ALK001)
PURPOSE: In Argentina, anaplastic lymphoma kinase (ALK) gene rearrangements occur in approximately 6.1% of non–small cell lung cancer (NSCLC) cases. Given the availability of second- and third-generation ALK inhibitors, real-world data are needed to inform optimal treatment strategies. However, access to these therapies remains limited for many patients. METHODS: We conducted a multicenter retrospective study of patients with metastatic ALK-positive NSCLC (ALKp) treated with first-line tyrosine kinase inhibitors (TKIs) from January 2014 to February 2024. Demographics, treatment patterns, clinical outcomes, and factors affecting treatment accessibility were analyzed. RESULTS: We identified 104 patients with ALKp. The median age was 55 years (IQR, 45-67); 86% had Eastern Cooperative Oncology Group ≤1, 58% were women, and 57% were nonsmokers. Brain metastases were present at diagnosis in 29%, with 50% receiving local treatment. First-line TKIs included alectinib (42%), crizotinib (30%), lorlatinib (16%), and brigatinib (12%). Crizotinib use was frequently due to limited access to new-generation TKIs. Adverse events occurred in 54%, with 21% grade 3 to 4. The objective response rate was 73%. At a median follow-up of 42 months, 48% experienced progression. Crizotinib was associated with higher risk of progression or death compared with newer TKIs (hazard ratio, 3.09 [95% CI, 1.75 to 5.5]; P = .01). CNS progression occurred in 18%, more often with crizotinib (42% v 8%, P = .04). Among those progressing, 82% received second-line therapy, most commonly lorlatinib or alectinib. The overall survival at 24 months was 81%, with 27% of patients deceased at data cutoff. CONCLUSION: This real-world study describes outcomes and treatment patterns among patients with ALKp in Argentina. It highlights disparities in access to optimal therapies and reinforces the need for equitable access to new-generation ALK inhibitors to improve clinical outcomes.
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400342
Treatment Trends in Metastatic Renal Clear Cell Carcinoma in Argentina
PURPOSE: Renal cell carcinoma (RCC) accounts for 2%-3% of adult cancers globally. In Argentina, RCC is the fifth most common cancer, with over 2,000 new patients annually. This study aims to evaluate treatment trends for patients with metastatic renal cell carcinoma (mRCC) in Argentina. METHODS: A retrospective study was conducted involving 689 patients with mRCC treated in Argentina between 2015 and 2022. The study analyzed treatment patterns and outcomes over time. RESULTS: Access to combination treatments for mRCC in Argentina has increased significantly, with 87% of patients receiving such therapies during the 2021-2022 period. The real-world data demonstrated that combination treatments in this Latin American population resulted in prolonged progression-free survival and improved overall response rate. CONCLUSION: The results underscore the importance of ensuring access to combination therapies for patients with mRCC in Latin America. These findings should inform public health policies aimed at guaranteeing access to effective combination therapies.
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400342
Treatment Trends in Metastatic Renal Clear Cell Carcinoma in Argentina
PURPOSE: Renal cell carcinoma (RCC) accounts for 2%-3% of adult cancers globally. In Argentina, RCC is the fifth most common cancer, with over 2,000 new patients annually. This study aims to evaluate treatment trends for patients with metastatic renal cell carcinoma (mRCC) in Argentina. METHODS: A retrospective study was conducted involving 689 patients with mRCC treated in Argentina between 2015 and 2022. The study analyzed treatment patterns and outcomes over time. RESULTS: Access to combination treatments for mRCC in Argentina has increased significantly, with 87% of patients receiving such therapies during the 2021-2022 period. The real-world data demonstrated that combination treatments in this Latin American population resulted in prolonged progression-free survival and improved overall response rate. CONCLUSION: The results underscore the importance of ensuring access to combination therapies for patients with mRCC in Latin America. These findings should inform public health policies aimed at guaranteeing access to effective combination therapies.